|
|
Abstract
Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in previously untreated HIV-infected children
M B Funk1, Z Elanjikal1, G Notheis2, R Linde1, C Koenigs1, U Wintergerst2, W Kreuz1
1University Children´s Hospital, Frankfurt/ Main, Germany; 2University Children´s Hospital, Munich, Germany
Background: In an intent-to-treat study reduction of viral load, increase of CD4 cell count, clinical benefit and adverse reactions were examined in HIV-infected previously untreated children receiving first line therapy with efavirenz (EFV).
Methods: The data of 10 perinatally infected children (median age: 5,8 years) were evaluated during a treatment period of 24 months. Viral load and CD4 cell count were measured every 4 –8 weeks. Plasma efavirenz though levels (Cmin) were assessed in all patients.
Results: At base line median CD4 cell count was 378 cells/ µl (21%) and median viral load was 350 000 copies / ml (5,5 log10).
After 24 months of treatment the median viral load reduction was > 3,5 log10 and HIV-1 RNA < 50 copies/ml was found in 8/ 10 children (80%). Median CD4 cell count increased to 721 cells/ µl (24%) after 3 months and was maintained at a level > 1000 cells/l (> 25%) after 24 months of treatment.
The Cmin-values ranged from 960 to 3340 ng/ ml (median: 1960 ng/ ml). The most common adverse effect was rash (4/ 10 children), but no hyperlipidaemia was recorded.
Conclusions: First line therapy with efavirenze and two NRTI was well tolerated by HIV-1 infected children and reduction of viral load seems to be similar or superior to protease inhibitor-containing regimens. Evaluation of plasma efavirenz though levels was useful to optimize treatment.
The XV International AIDS Conference
Abstract no.
TuPeB4395
Suggested Citation
" M B Funk , , et al.
Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in previously untreated HIV-infected children
.
Poster Exhibition:
The XV International AIDS Conference:
Abstract no.
TuPeB4395"
|
|
|